MedTrace Logo

Nebulized Colistin for Gram Negative VAP Prevention.

NCT04208945 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2019-12-23

No results posted yet for this study

Summary

Colistin is used as an elective treatment of infections of multi drug resistant gram negative bacteria. Until now colistin is used in the therapeutic regimen of these infections intravenous or nebulized. There are a plenty of studies about the efficacy of nebulized colistin in the therapy of pseudomonas aeruginosa pneumonia in patients with cystic fibrosis and in the therapy of ventilator associated pneumonia in ICU. On the other hand there are only a few studies about the use of nebulized colistin in the prevention of ventilator associated pneumonia whereas the role of nebulized colistin in the prevention of severe forms of pneumonia such as VAP due to multi drug resistant gram negative bacteria are limited.

This double blinded randomized trial aim to investigate the effect of nebulized colistin on the incidence of patients with due to gram negative bacteria in the ICU compared to nebulized normal saline.

Conditions

  • Pneumonia, Ventilator-associated
  • Gram-Negative Pneumonia

Interventions

DRUG

Colistin

500000 units of inhaled colistin three times daily for 10 days

Sponsors & Collaborators

  • University of Thessaly

    lead OTHER

Principal Investigators

  • DEMOSTHENES MAKRIS, as prof · INTENSIVE CARE DEPARTMENT UNIVERSITY HOSPITAL

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2021-04-30
Completion
2021-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208945 on ClinicalTrials.gov